NEW YORK (GenomeWeb) – Advanced Cell Diagnostics announced today a preferred partnership agreement with Dundee, UK-based MicroMatrices to develop applications of its RNAscope technology.
ACD's RNAscope assays allow for single RNA molecule detection of formalin-fixed, paraffin-embedded tissue samples, offering quantitative molecular detection with morphological context in a single assay. MicroMatrices has expertise in using RNAscope to detect RNA-based biomarkers in situ, the companies said in a statement, and will now aim to develop preclinical applications of the technology.
"The power and versatility of RNAscope has been an invaluable tool to enable us to solve mode of action/efficacy/toxicity challenges for our clients in the pharmaceutical, agrochemical, and chemical industries," Simon Plummer, managing director of MicroMatrices, said.
Financial and other terms of the deal were not provided.
MicroMatrices is a service provider specializing in high resolution cell type-specific analysis to characterize toxicological responses in different cell types and tissues.
Hayward, Calif.-based ACD develops cell and tissue-based diagnostic tests for personalized medicine.